Home La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)
 

Keywords :   


La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)

2014-07-30 09:57:01| drugdiscoveryonline Home Page

La Jolla Pharmaceutical Company (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases,recently announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial

Tags: data positive oral pharmaceutical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.11 SGY-PM910ZW
25.11Pioneer DJ DDJ-SP1 DJ
25.11Dr.STONE
25.11
25.1146 dvd
25.11 SONY 4 CUH-1100A
25.11 COMPLETE DVD-BOX6
25.11DAHON /(330mm8°)
More »